(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 94.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Cormedix's revenue in 2025 is $43,472,170.On average, 2 Wall Street analysts forecast CRMD's revenue for 2025 to be $8,397,693,467, with the lowest CRMD revenue forecast at $8,160,757,729, and the highest CRMD revenue forecast at $8,634,629,204. On average, 2 Wall Street analysts forecast CRMD's revenue for 2026 to be $14,271,222,852, with the lowest CRMD revenue forecast at $12,312,184,724, and the highest CRMD revenue forecast at $16,230,260,979.
In 2027, CRMD is forecast to generate $21,197,111,929 in revenue, with the lowest revenue forecast at $21,197,111,929 and the highest revenue forecast at $21,197,111,929.